Nina Kushner, MD
Internal Medicine · Brooklyn, NYNPI 1104801091
Payments from drug & device makers
Across 224 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sumitomo Pharma America, Inc.$531
- Amgen$483
- Lilly USA, LLC$284
- Urovant Sciences Inc$253
- Novo Nordisk$239
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,223100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $1,477 |
| Sumitomo Pharma America, Inc. | 22 | $531 |
| Amgen | 20 | $483 |
| Lilly USA, LLC | 15 | $284 |
| Urovant Sciences Inc | 9 | $253 |
| Novo Nordisk | 10 | $239 |
| Axsome Therapeutics, Inc. | 8 | $217 |
| AstraZeneca | 8 | $172 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $172 |
| Aimmune Therapeutics, Inc. | 6 | $170 |
| GSK | 7 | $165 |
| Merck | 8 | $158 |
| Novartis | 4 | $86 |
| Amarin Pharma, Inc. | 4 | $79 |
| Boehringer Ingelheim | 3 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Philips North America LLC | 2 | $69 |
| Pfizer | 3 | $69 |
| Bayer | 2 | $69 |
| Phathom Pharmaceuticals, Inc. | 2 | $61 |
| Scilex Pharmaceuticals Inc. | 2 | $46 |
| Astellas Pharma US Inc | 3 | $43 |
| Shield Therapeutics Inc | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Exact Sciences | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$116
How this compares
$5,235 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 185 | $253,771 |
| EliquisApixaban | 275 | $216,227 |
| JardianceEmpagliflozin | 226 | $200,230 |
| CreonLipase/Protease/Amylase | 152 | $129,949 |
| MounjaroTirzepatide | 106 | $125,140 |
| LinzessLinaclotide | 194 | $115,665 |
| Diclofenac Sodium | 244 | $105,858 |
| JanuviaSitagliptin Phosphate | 97 | $76,136 |
| TrulicityDulaglutide | 70 | $74,507 |
| VascepaIcosapent Ethyl | 189 | $70,019 |
| ZenpepLipase/Protease/Amylase | 67 | $55,246 |
| Metformin Er GastricMetformin Hcl | 59 | $51,974 |
| Nurtec OdtRimegepant Sulfate | 16 | $49,322 |
| GemtesaVibegron | 73 | $46,312 |
| EntrestoSacubitril/Valsartan | 34 | $44,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Ubrelvy | $1,477 | $282,209362 claims |
| PfizerEliquis, Nurtec Odt | $69 | $265,550291 claims |
| Novo NordiskOzempic | $239 | $253,771185 claims |
| Boehringer IngelheimJardiance, Tradjenta | $78 | $237,966276 claims |
| Lilly USA, LLCMounjaro, Trulicity | $284 | $199,647176 claims |
| MerckJanuvia, Janumet, Janumet Xr | $158 | $137,379177 claims |
| Aimmune Therapeutics, Inc.Zenpep | $170 | $55,24667 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $165 | $54,74798 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $72 | $51,84699 claims |
| AstraZenecaFarxiga, Crestor | $172 | $49,70371 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $531 | $46,31273 claims |
| NovartisEntresto | $86 | $44,00934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.